ImmunoGen, Inc.

2023 Q1 Form 10-K Financial Statement

#000155837023002558 Filed on March 01, 2023

View on sec.gov

Income Statement

Concept 2023 Q1 2022 Q4 2022

Balance Sheet

Concept 2023 Q1 2022 Q4 2022
SHORT-TERM ASSETS
Cash & Short-Term Investments $201.2M $275.1M $275.1M
YoY Change -54.03% -42.54% -42.53%
Cash & Equivalents $201.2M $275.1M $275.1M
Short-Term Investments $0.00 $0.00
Other Short-Term Assets $10.96M $11.01M $11.01M
YoY Change 24.39% 50.3% 50.3%
Inventory $614.0K
Prepaid Expenses
Receivables $28.59M $14.13M $14.13M
Other Receivables $2.455M $3.851M $3.851M
Total Short-Term Assets $243.9M $304.1M $304.1M
YoY Change -46.61% -39.18% -39.18%
LONG-TERM ASSETS
Property, Plant & Equipment $4.067M $4.377M $14.61M
YoY Change -8.21% -6.13% -14.35%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets $14.50M $14.01M $30.21M
YoY Change 67.16% 60.84% 246.77%
Total Long-Term Assets $44.48M $44.82M $44.82M
YoY Change 77.99% 73.93% 73.93%
TOTAL ASSETS
Total Short-Term Assets $243.9M $304.1M $304.1M
Total Long-Term Assets $44.48M $44.82M $44.82M
Total Assets $288.3M $348.9M $348.9M
YoY Change -40.14% -33.63% -33.63%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $32.26M $45.35M $45.35M
YoY Change 100.87% 146.03% 146.03%
Accrued Expenses $46.91M $53.99M $53.99M
YoY Change 30.67% 68.28% 68.28%
Deferred Revenue $13.44M $13.86M
YoY Change -42.59% -68.76%
Short-Term Debt $0.00 $0.00 $0.00
YoY Change
Long-Term Debt Due $9.000M $8.700M $8.700M
YoY Change 3.45% 42.62% 42.62%
Total Short-Term Liabilities $101.6M $121.9M $121.9M
YoY Change 20.82% 20.72% 20.72%
LONG-TERM LIABILITIES
Long-Term Debt $0.00 $0.00 $0.00
YoY Change
Other Long-Term Liabilities $300.0K $300.0K $71.25M
YoY Change -55.62% -77.03% -28.2%
Total Long-Term Liabilities $300.0K $300.0K $71.25M
YoY Change -55.62% -77.03% -28.2%
TOTAL LIABILITIES
Total Short-Term Liabilities $101.6M $121.9M $121.9M
Total Long-Term Liabilities $300.0K $300.0K $71.25M
Total Liabilities $166.4M $193.1M $193.1M
YoY Change -5.03% -3.53% -3.53%
SHAREHOLDERS EQUITY
Retained Earnings -$1.700B -$1.700B
YoY Change 13.33% 15.56%
Common Stock $1.857B $1.850B
YoY Change 3.07% 2.96%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity $121.9M $155.8M $155.8M
YoY Change
Total Liabilities & Shareholders Equity $288.3M $348.9M $348.9M
YoY Change -40.14% -33.63% -33.63%

Cashflow Statement

Concept 2023 Q1 2022 Q4 2022

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
CY2022Q4 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
CY2021Q4 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
CY2022 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
253631000
CY2021 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
206147000
CY2020 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
176153000
CY2021Q4 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0
CY2022Q4 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0
CY2022 dei Entity Central Index Key
EntityCentralIndexKey
0000855654
CY2022 dei Document Fiscal Year Focus
DocumentFiscalYearFocus
2022
CY2022 dei Document Fiscal Period Focus
DocumentFiscalPeriodFocus
FY
CY2022Q4 us-gaap Preferred Stock Value
PreferredStockValue
CY2021Q4 us-gaap Preferred Stock Value
PreferredStockValue
CY2022Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
226046000
CY2021Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
220361000
CY2022 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.88
CY2021 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.68
CY2020 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.25
CY2022 dei Amendment Flag
AmendmentFlag
false
CY2022 dei Document Type
DocumentType
10-K
CY2022 dei Document Annual Report
DocumentAnnualReport
true
CY2022 dei Entity File Number
EntityFileNumber
0-17999
CY2022 dei Document Period End Date
DocumentPeriodEndDate
2022-12-31
CY2022 dei Current Fiscal Year End Date
CurrentFiscalYearEndDate
--12-31
CY2022 dei Document Transition Report
DocumentTransitionReport
false
CY2022 dei Entity Registrant Name
EntityRegistrantName
ImmunoGen, Inc.
CY2022 dei Entity Incorporation State Country Code
EntityIncorporationStateCountryCode
MA
CY2022 dei Entity Tax Identification Number
EntityTaxIdentificationNumber
04-2726691
CY2022 dei Entity Address Address Line1
EntityAddressAddressLine1
830 Winter Street
CY2022 dei Entity Address City Or Town
EntityAddressCityOrTown
Waltham
CY2022 dei Entity Address State Or Province
EntityAddressStateOrProvince
MA
CY2022 dei Entity Address Postal Zip Code
EntityAddressPostalZipCode
02451
CY2022 dei City Area Code
CityAreaCode
781
CY2022 dei Local Phone Number
LocalPhoneNumber
895-0600
CY2022 dei Security12b Title
Security12bTitle
Common Stock
CY2022 dei Trading Symbol
TradingSymbol
IMGN
CY2022 dei Security Exchange Name
SecurityExchangeName
NASDAQ
CY2022 dei Entity Well Known Seasoned Issuer
EntityWellKnownSeasonedIssuer
Yes
CY2022 dei Entity Voluntary Filers
EntityVoluntaryFilers
No
CY2022 dei Entity Current Reporting Status
EntityCurrentReportingStatus
Yes
CY2022 dei Entity Interactive Data Current
EntityInteractiveDataCurrent
Yes
CY2022 dei Entity Filer Category
EntityFilerCategory
Large Accelerated Filer
CY2022 dei Entity Small Business
EntitySmallBusiness
false
CY2022 dei Entity Emerging Growth Company
EntityEmergingGrowthCompany
false
CY2022 dei Icfr Auditor Attestation Flag
IcfrAuditorAttestationFlag
true
CY2022 dei Entity Shell Company
EntityShellCompany
false
CY2022Q2 dei Entity Public Float
EntityPublicFloat
989665866
CY2023Q1 dei Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
226046108
CY2022 dei Auditor Firm
AuditorFirmId
42
CY2022 dei Auditor Name
AuditorName
Ernst & Young LLP
CY2022 dei Auditor Location
AuditorLocation
Boston, Massachusetts
CY2022Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
275138000
CY2021Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
478750000
CY2022Q4 us-gaap Accounts Receivable Gross Current
AccountsReceivableGrossCurrent
12596000
CY2021Q4 us-gaap Accounts Receivable Gross Current
AccountsReceivableGrossCurrent
4467000
CY2022Q4 us-gaap Unbilled Receivables Current
UnbilledReceivablesCurrent
1531000
CY2021Q4 us-gaap Unbilled Receivables Current
UnbilledReceivablesCurrent
2345000
CY2022Q4 us-gaap Contract With Customer Asset Gross Current
ContractWithCustomerAssetGrossCurrent
0
CY2021Q4 us-gaap Contract With Customer Asset Gross Current
ContractWithCustomerAssetGrossCurrent
3000000
CY2022Q4 imgn Non Cash Royalty Receivable
NonCashRoyaltyReceivable
3851000
CY2021Q4 imgn Non Cash Royalty Receivable
NonCashRoyaltyReceivable
4115000
CY2022Q4 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
11005000
CY2021Q4 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
7322000
CY2022Q4 us-gaap Assets Current
AssetsCurrent
304121000
CY2021Q4 us-gaap Assets Current
AssetsCurrent
499999000
CY2022Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
4377000
CY2021Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
4663000
CY2022Q4 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
10231000
CY2021Q4 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
12392000
CY2022Q4 us-gaap Inventory Noncurrent
InventoryNoncurrent
16196000
CY2022Q4 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
14011000
CY2021Q4 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
8711000
CY2022Q4 us-gaap Assets
Assets
348936000
CY2021Q4 us-gaap Assets
Assets
525765000
CY2022Q4 us-gaap Contract With Customer Liability Current
ContractWithCustomerLiabilityCurrent
13856000
CY2021Q4 us-gaap Contract With Customer Liability Current
ContractWithCustomerLiabilityCurrent
44351000
CY2022Q4 us-gaap Liabilities Current
LiabilitiesCurrent
121858000
CY2022Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
45353000
CY2021Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
18434000
CY2022Q4 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
11111000
CY2021Q4 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
5469000
CY2022Q4 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
38783000
CY2021Q4 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
23077000
CY2022 imgn Deferred Financing Costs Liability Sale Of Future Royalties Current
DeferredFinancingCostsLiabilitySaleOfFutureRoyaltiesCurrent
162000
CY2021 imgn Deferred Financing Costs Liability Sale Of Future Royalties Current
DeferredFinancingCostsLiabilitySaleOfFutureRoyaltiesCurrent
198000
CY2022Q4 imgn Liability Related To Sale Of Future Royalties Current
LiabilityRelatedToSaleOfFutureRoyaltiesCurrent
8659000
CY2021Q4 imgn Liability Related To Sale Of Future Royalties Current
LiabilityRelatedToSaleOfFutureRoyaltiesCurrent
6077000
CY2022Q4 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
4096000
CY2021Q4 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
3537000
CY2021Q4 us-gaap Liabilities Current
LiabilitiesCurrent
100945000
CY2022Q4 us-gaap Contract With Customer Liability Noncurrent
ContractWithCustomerLiabilityNoncurrent
36355000
CY2021Q4 us-gaap Contract With Customer Liability Noncurrent
ContractWithCustomerLiabilityNoncurrent
47717000
CY2022Q4 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
11148000
CY2021Q4 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
15244000
CY2022Q4 imgn Deferred Financing Costs Liability Sale Of Future Royalties Noncurrent
DeferredFinancingCostsLiabilitySaleOfFutureRoyaltiesNoncurrent
205000
CY2021Q4 imgn Deferred Financing Costs Liability Sale Of Future Royalties Noncurrent
DeferredFinancingCostsLiabilitySaleOfFutureRoyaltiesNoncurrent
381000
CY2022Q4 imgn Liability Related To Sale Of Future Royalties Noncurrent
LiabilityRelatedToSaleOfFutureRoyaltiesNoncurrent
23449000
CY2021Q4 imgn Liability Related To Sale Of Future Royalties Noncurrent
LiabilityRelatedToSaleOfFutureRoyaltiesNoncurrent
34967000
CY2022Q4 us-gaap Other Liabilities Noncurrent
OtherLiabilitiesNoncurrent
300000
CY2021Q4 us-gaap Other Liabilities Noncurrent
OtherLiabilitiesNoncurrent
1306000
CY2022Q4 us-gaap Liabilities
Liabilities
193110000
CY2021Q4 us-gaap Liabilities
Liabilities
200179000
CY2021Q4 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.01
CY2022Q4 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.01
CY2021Q4 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
5000000
CY2022Q4 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
5000000
CY2021Q4 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0
CY2022Q4 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0
CY2021Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.01
CY2022Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.01
CY2021Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
600000000
CY2022Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
600000000
CY2022Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
226046000
CY2021Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
220361000
CY2022Q4 us-gaap Common Stock Value
CommonStockValue
2260000
CY2021Q4 us-gaap Common Stock Value
CommonStockValue
2204000
CY2022Q4 us-gaap Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
1847638000
CY2021Q4 us-gaap Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
1794525000
CY2022Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-1694072000
CY2021Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-1471143000
CY2022Q4 us-gaap Stockholders Equity
StockholdersEquity
155826000
CY2021Q4 us-gaap Stockholders Equity
StockholdersEquity
325586000
CY2022Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
348936000
CY2021Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
525765000
CY2022 us-gaap Revenue From Contract With Customer Including Assessed Tax
RevenueFromContractWithCustomerIncludingAssessedTax
108782000
CY2021 us-gaap Revenue From Contract With Customer Including Assessed Tax
RevenueFromContractWithCustomerIncludingAssessedTax
69856000
CY2020 us-gaap Revenue From Contract With Customer Including Assessed Tax
RevenueFromContractWithCustomerIncludingAssessedTax
132299000
CY2022 imgn Cost Of Goods And Services Sold Operating
CostOfGoodsAndServicesSoldOperating
176000
CY2022 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
213370000
CY2021 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
151117000
CY2020 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
114592000
CY2022 us-gaap Selling General And Administrative Expense
SellingGeneralAndAdministrativeExpense
116129000
CY2021 us-gaap Selling General And Administrative Expense
SellingGeneralAndAdministrativeExpense
43812000
CY2020 us-gaap Selling General And Administrative Expense
SellingGeneralAndAdministrativeExpense
38600000
CY2020 us-gaap Restructuring Charges
RestructuringCharges
1487000
CY2022 us-gaap Operating Expenses
OperatingExpenses
329675000
CY2021 us-gaap Operating Expenses
OperatingExpenses
194929000
CY2022 us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
1364000
CY2020 us-gaap Operating Expenses
OperatingExpenses
154679000
CY2022 us-gaap Operating Income Loss
OperatingIncomeLoss
-220893000
CY2021 us-gaap Operating Income Loss
OperatingIncomeLoss
-125073000
CY2021 us-gaap Investment Income Net
InvestmentIncomeNet
51000
CY2020 us-gaap Operating Income Loss
OperatingIncomeLoss
-22380000
CY2022 us-gaap Investment Income Net
InvestmentIncomeNet
4341000
CY2021 us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
1434000
CY2020 us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
917000
CY2020 us-gaap Investment Income Net
InvestmentIncomeNet
729000
CY2022 imgn Non Cash Interest Expense From Sale Of Future Royalties
NonCashInterestExpenseFromSaleOfFutureRoyalties
4165000
CY2021 imgn Non Cash Interest Expense From Sale Of Future Royalties
NonCashInterestExpenseFromSaleOfFutureRoyalties
13103000
CY2020 imgn Non Cash Interest Expense From Sale Of Future Royalties
NonCashInterestExpenseFromSaleOfFutureRoyalties
23107000
CY2021 us-gaap Interest Expense Debt
InterestExpenseDebt
47000
CY2020 us-gaap Interest Expense Debt
InterestExpenseDebt
95000
CY2022 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
-994000
CY2021 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
-1131000
CY2020 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
481000
CY2022 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-221711000
CY2021 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-139303000
CY2020 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-44372000
CY2022 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
1218000
CY2022 us-gaap Net Income Loss
NetIncomeLoss
-222929000
CY2021 us-gaap Net Income Loss
NetIncomeLoss
-139303000
CY2020 us-gaap Net Income Loss
NetIncomeLoss
-44372000
CY2022 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.88
CY2021 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.68
CY2020 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.25
CY2022 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
253631000
CY2021 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
206147000
CY2020 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
176153000
CY2022 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-222929000
CY2021 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-139303000
CY2020 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-44372000
CY2019Q4 us-gaap Stockholders Equity
StockholdersEquity
-76121000
CY2020 us-gaap Net Income Loss
NetIncomeLoss
-44372000
CY2020 imgn Stock Issued During Period Value Stock Options Exercised And Employee Stock Purchase Plan
StockIssuedDuringPeriodValueStockOptionsExercisedAndEmployeeStockPurchasePlan
1471000
CY2020 us-gaap Stock Issued During Period Value New Issues
StockIssuedDuringPeriodValueNewIssues
194271000
CY2020 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
13978000
CY2020 imgn Adjustments To Additional Paid In Capital Directors Deferred Share Based Compensation
AdjustmentsToAdditionalPaidInCapitalDirectorsDeferredShareBasedCompensation
343000
CY2020Q4 us-gaap Stockholders Equity
StockholdersEquity
89570000
CY2021 us-gaap Net Income Loss
NetIncomeLoss
-139303000
CY2021 imgn Stock Issued During Period Value Stock Options Exercised And Employee Stock Purchase Plan
StockIssuedDuringPeriodValueStockOptionsExercisedAndEmployeeStockPurchasePlan
3769000
CY2021 us-gaap Stock Issued During Period Value New Issues
StockIssuedDuringPeriodValueNewIssues
154030000
CY2021 imgn Prefunded Warrant Net Of Issuance Costs
PrefundedWarrantNetOfIssuanceCosts
199045000
CY2021 us-gaap Debt Conversion Converted Instrument Amount1
DebtConversionConvertedInstrumentAmount1
1000000
CY2021 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
16794000
CY2021 imgn Adjustments To Additional Paid In Capital Directors Deferred Share Based Compensation
AdjustmentsToAdditionalPaidInCapitalDirectorsDeferredShareBasedCompensation
681000
CY2021Q4 us-gaap Stockholders Equity
StockholdersEquity
325586000
CY2022 us-gaap Net Income Loss
NetIncomeLoss
-222929000
CY2022 us-gaap Stock Issued During Period Value New Issues
StockIssuedDuringPeriodValueNewIssues
25649000
CY2022 imgn Stock Issued During Period Value Stock Options Exercised And Employee Stock Purchase Plan
StockIssuedDuringPeriodValueStockOptionsExercisedAndEmployeeStockPurchasePlan
1905000
CY2022 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
24899000
CY2022 imgn Adjustments To Additional Paid In Capital Directors Deferred Share Based Compensation
AdjustmentsToAdditionalPaidInCapitalDirectorsDeferredShareBasedCompensation
716000
CY2022Q4 us-gaap Stockholders Equity
StockholdersEquity
155826000
CY2022 us-gaap Profit Loss
ProfitLoss
-222929000
CY2021 us-gaap Profit Loss
ProfitLoss
-139303000
CY2022Q4 us-gaap Revenue Remaining Performance Obligation Percentage
RevenueRemainingPerformanceObligationPercentage
0.70
CY2022Q4 us-gaap Revenue Remaining Performance Obligation Percentage
RevenueRemainingPerformanceObligationPercentage
0.02
CY2020 us-gaap Profit Loss
ProfitLoss
-44372000
CY2022 imgn Non Cash Royalty Revenue Related To Sale Of Future Royalties
NonCashRoyaltyRevenueRelatedToSaleOfFutureRoyalties
12836000
CY2021 imgn Non Cash Royalty Revenue Related To Sale Of Future Royalties
NonCashRoyaltyRevenueRelatedToSaleOfFutureRoyalties
39155000
CY2020 imgn Non Cash Royalty Revenue Related To Sale Of Future Royalties
NonCashRoyaltyRevenueRelatedToSaleOfFutureRoyalties
68529000
CY2022 imgn Non Cash Interest Expense From Sale Of Future Royalties
NonCashInterestExpenseFromSaleOfFutureRoyalties
4165000
CY2021 imgn Non Cash Interest Expense From Sale Of Future Royalties
NonCashInterestExpenseFromSaleOfFutureRoyalties
13103000
CY2020 imgn Non Cash Interest Expense From Sale Of Future Royalties
NonCashInterestExpenseFromSaleOfFutureRoyalties
23107000
CY2022 us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
1783000
CY2021 us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
2017000
CY2020 us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
2101000
CY2020 us-gaap Gain Loss On Sale Of Property Plant Equipment
GainLossOnSaleOfPropertyPlantEquipment
691000
CY2022 us-gaap Share Based Compensation
ShareBasedCompensation
25615000
CY2021 us-gaap Share Based Compensation
ShareBasedCompensation
17475000
CY2020 us-gaap Share Based Compensation
ShareBasedCompensation
14321000
CY2022 us-gaap Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
8129000
CY2021 us-gaap Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
4432000
CY2020 us-gaap Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
-7465000
CY2022 imgn Increase Decrease In Customer Asset
IncreaseDecreaseInCustomerAsset
-814000
CY2021 imgn Increase Decrease In Customer Asset
IncreaseDecreaseInCustomerAsset
2334000
CY2020 imgn Increase Decrease In Customer Asset
IncreaseDecreaseInCustomerAsset
-990000
CY2022 us-gaap Increase Decrease In Inventories
IncreaseDecreaseInInventories
16196000
CY2022 us-gaap Increase Decrease In Contract With Customer Asset
IncreaseDecreaseInContractWithCustomerAsset
-3000000
CY2021 us-gaap Increase Decrease In Contract With Customer Asset
IncreaseDecreaseInContractWithCustomerAsset
3000000
CY2020 us-gaap Increase Decrease In Contract With Customer Asset
IncreaseDecreaseInContractWithCustomerAsset
-3631000
CY2022 us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
3683000
CY2021 us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
-579000
CY2020 us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
2476000
CY2022 us-gaap Right Of Use Asset Obtained In Exchange For Operating Lease Liability
RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability
2161000
CY2021 us-gaap Right Of Use Asset Obtained In Exchange For Operating Lease Liability
RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability
1680000
CY2020 us-gaap Right Of Use Asset Obtained In Exchange For Operating Lease Liability
RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability
1515000
CY2022 us-gaap Increase Decrease In Other Operating Assets
IncreaseDecreaseInOtherOperatingAssets
5300000
CY2021 us-gaap Increase Decrease In Other Operating Assets
IncreaseDecreaseInOtherOperatingAssets
-2275000
CY2020 us-gaap Increase Decrease In Other Operating Assets
IncreaseDecreaseInOtherOperatingAssets
7202000
CY2022 us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
26735000
CY2021 us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
9148000
CY2020 us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
-819000
CY2022 us-gaap Increase Decrease In Employee Related Liabilities
IncreaseDecreaseInEmployeeRelatedLiabilities
5642000
CY2021 us-gaap Increase Decrease In Employee Related Liabilities
IncreaseDecreaseInEmployeeRelatedLiabilities
849000
CY2020 us-gaap Increase Decrease In Employee Related Liabilities
IncreaseDecreaseInEmployeeRelatedLiabilities
-4100000
CY2022 us-gaap Increase Decrease In Other Accrued Liabilities
IncreaseDecreaseInOtherAccruedLiabilities
14750000
CY2021 us-gaap Increase Decrease In Other Accrued Liabilities
IncreaseDecreaseInOtherAccruedLiabilities
-7261000
CY2020 us-gaap Increase Decrease In Other Accrued Liabilities
IncreaseDecreaseInOtherAccruedLiabilities
16734000
CY2022 us-gaap Increase Decrease In Contract With Customer Liability
IncreaseDecreaseInContractWithCustomerLiability
-41857000
CY2021 us-gaap Increase Decrease In Contract With Customer Liability
IncreaseDecreaseInContractWithCustomerLiability
-18041000
CY2020 us-gaap Increase Decrease In Contract With Customer Liability
IncreaseDecreaseInContractWithCustomerLiability
-17323000
CY2022 imgn Operating Lease Liability Amortization
OperatingLeaseLiabilityAmortization
-3537000
CY2021 imgn Operating Lease Liability Amortization
OperatingLeaseLiabilityAmortization
-3016000
CY2020 imgn Operating Lease Liability Amortization
OperatingLeaseLiabilityAmortization
-2972000
CY2022 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-229802000
CY2021 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-169416000
CY2020 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-78620000
CY2020 us-gaap Proceeds From Sale Of Machinery And Equipment
ProceedsFromSaleOfMachineryAndEquipment
1426000
CY2022 us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-1364000
CY2021 imgn Accumulated Depreciation Impairment Liquidate Equipment
AccumulatedDepreciationImpairmentLiquidateEquipment
1400000
CY2021 us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-1434000
CY2020 us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
509000
CY2021 us-gaap Repayments Of Convertible Debt
RepaymentsOfConvertibleDebt
1100000
CY2022 us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
1905000
CY2021 us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
3769000
CY2020 us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
1471000
CY2020 us-gaap Payments Of Loan Costs
PaymentsOfLoanCosts
391000
CY2021 us-gaap Payments Of Loan Costs
PaymentsOfLoanCosts
391000
CY2022 us-gaap Payments Of Loan Costs
PaymentsOfLoanCosts
391000
CY2021 us-gaap Proceeds From Issuance Of Warrants
ProceedsFromIssuanceOfWarrants
199045000
CY2022 us-gaap Payments Of Stock Issuance Costs
PaymentsOfStockIssuanceCosts
373000
CY2021 us-gaap Payments Of Stock Issuance Costs
PaymentsOfStockIssuanceCosts
701000
CY2022 us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
25649000
CY2021 us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
154030000
CY2020 us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
194271000
CY2022 us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
27554000
CY2021 us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
355744000
CY2020 us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
195742000
CY2022 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
-203612000
CY2021 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
184894000
CY2020 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
117631000
CY2021Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
478750000
CY2020Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
293856000
CY2019Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
176225000
CY2022Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
275138000
CY2021Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
478750000
CY2020Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
293856000
CY2021 us-gaap Interest Paid Net
InterestPaidNet
47000
CY2020 us-gaap Interest Paid Net
InterestPaidNet
95000
CY2022 us-gaap Nature Of Operations
NatureOfOperations
<p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 10pt 0pt;"><b style="font-weight:bold;">IMMUNOGEN, INC.</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 10pt 0pt;"><b style="font-weight:bold;">NOTES TO CONSOLIDATED FINANCIAL STATEMENTS</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 6pt 0pt;"><span style="display:inline-block;text-indent:0pt;width:36pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;">A.</b></span><b style="font-weight:bold;">Nature of Business and Plan of Operations</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 6pt 0pt;">ImmunoGen, Inc. (the Company) was incorporated in Massachusetts in 1981 and is focused on the development and commercialization of antibody-drug conjugates, or ADCs. On November 14, 2022, the U.S. Food and Drug Administration (FDA) granted accelerated approval for ELAHERE™ (mirvetuximab soravtansine-gynx) for the treatment of adult patients with folate receptor alpha (FRα)-positive, platinum-resistant epithelial ovarian, fallopian tube, or primary peritoneal cancer, who have received one to three prior systemic treatment regimens. ELAHERE was approved under FDA's accelerated approval program based on objective response rate (ORR), duration of response (DOR), and safety data from the pivotal SORAYA trial. Continued approval may be contingent upon verification and description of clinical benefit in a confirmatory trial.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 6pt 0pt;">The Company has generally incurred operating losses and negative cash flows from operations since inception, incurred a net loss of $222.9 million during the year ended December 31, 2022, and had an accumulated deficit of approximately $1.7 billion as of December 31, 2022. The Company has primarily funded these losses through payments received from its collaborations and equity, convertible debt, and other financings such as royalty financing transactions. Until the Company can generate significant cash flows from sales of ELAHERE, management expects to continue to generate substantial operating losses for at least the near term as the Company incurs significant operating expenses related to research and development and selling and marketing of ELAHERE.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:41.05pt;margin:6pt 0pt 0pt 0pt;">At December 31, 2022, the Company had $275.1 million of cash and cash equivalents on hand. The Company’s current level of cash and cash equivalents is not sufficient to meet its current operating plans for the next twelve months following the issuance of these financial statements. As a result, substantial doubt is deemed to exist regarding the Company’s ability to continue as a going concern for a period of one year from the issuance of these financial statements. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:41.05pt;margin:6pt 0pt 0pt 0pt;">The Company plans to meet its operating cash flow requirements with its current cash and cash equivalents, cash generated from commercial sales of ELAHERE, milestone payments from new or existing collaborations, and additional funds accessed through equity, debt, or other financings such as royalty financing transactions, as well as cash preservation activities. Such activities may not succeed. The failure of the Company to obtain sufficient funds on acceptable terms could have a material adverse effect on the Company’s business, results of operations, and financial condition and require the Company to defer or limit some or all of its research, development, clinical and/or commercial projects, including trials to support potential label expansion of ELAHERE.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:41.05pt;margin:6pt 0pt 6pt 0pt;">The accompanying consolidated financial statements have been prepared on a going concern basis, which contemplates the realization of assets and satisfaction of liabilities in the ordinary course of business. The consolidated financial statements do not include any adjustments relating to the recoverability and classification of recorded asset amounts or the amounts and classification of liabilities that might result from the outcome of this uncertainty.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 6pt 0pt;">The Company is subject to risks common to companies in the biotechnology industry including, but not limited to, the development by its competitors of new technological innovations, dependence on key personnel, protection of proprietary technology, manufacturing and marketing limitations, challenges entering into new collaborations, complexities associated with managing collaboration arrangements, third-party reimbursements, and compliance with governmental regulations.</p>
CY2022 us-gaap Profit Loss
ProfitLoss
-222900000
CY2022Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-1700000000
CY2022Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
275100000
CY2022 us-gaap Use Of Estimates
UseOfEstimates
<p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:18pt;text-indent:-18pt;margin:0pt 0pt 6pt 36pt;"><i style="font-style:italic;">Use of Estimates</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 6pt 0pt;">The preparation of financial statements in conformity with accounting principles generally accepted in the United States (U.S.) requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. Actual results could differ from those estimates.</p>
CY2022Q4 imgn Upfront Fee Entitled To Receive
UpfrontFeeEntitledToReceive
15000000.0
CY2022Q4 us-gaap Revenue Remaining Performance Obligation
RevenueRemainingPerformanceObligation
50200000
CY2022Q4 us-gaap Revenue Remaining Performance Obligation Percentage
RevenueRemainingPerformanceObligationPercentage
0.28
CY2021Q4 us-gaap Contract With Customer Asset Gross Current
ContractWithCustomerAssetGrossCurrent
3000000
CY2022 us-gaap Contract With Customer Asset Reclassified To Receivable
ContractWithCustomerAssetReclassifiedToReceivable
-3000000
CY2022Q4 us-gaap Contract With Customer Asset Gross Current
ContractWithCustomerAssetGrossCurrent
0
CY2021Q4 us-gaap Contract With Customer Liability
ContractWithCustomerLiability
92068000
CY2022 us-gaap Contract With Customer Liability Increase Decrease For Contract Acquired In Business Combination
ContractWithCustomerLiabilityIncreaseDecreaseForContractAcquiredInBusinessCombination
7605000
CY2022 us-gaap Contract With Customer Liability Change In Timeframe Performance Obligation Satisfied Revenue Recognized
ContractWithCustomerLiabilityChangeInTimeframePerformanceObligationSatisfiedRevenueRecognized
49462000
CY2022Q4 us-gaap Contract With Customer Liability
ContractWithCustomerLiability
50211000
CY2021 us-gaap Contract With Customer Asset Increase Decrease For Contract Acquired In Business Combination
ContractWithCustomerAssetIncreaseDecreaseForContractAcquiredInBusinessCombination
-5500000
CY2021 us-gaap Contract With Customer Asset Reclassified To Receivable
ContractWithCustomerAssetReclassifiedToReceivable
-2500000
CY2021Q4 us-gaap Contract With Customer Asset Gross Current
ContractWithCustomerAssetGrossCurrent
3000000
CY2020Q4 us-gaap Contract With Customer Liability
ContractWithCustomerLiability
110109000
CY2021 us-gaap Contract With Customer Liability Increase Decrease For Contract Acquired In Business Combination
ContractWithCustomerLiabilityIncreaseDecreaseForContractAcquiredInBusinessCombination
4753000
CY2021 us-gaap Contract With Customer Liability Change In Timeframe Performance Obligation Satisfied Revenue Recognized
ContractWithCustomerLiabilityChangeInTimeframePerformanceObligationSatisfiedRevenueRecognized
22794000
CY2021Q4 us-gaap Contract With Customer Liability
ContractWithCustomerLiability
92068000
CY2022 us-gaap Contract With Customer Liability Revenue Recognized
ContractWithCustomerLiabilityRevenueRecognized
49462000
CY2021 us-gaap Contract With Customer Liability Revenue Recognized
ContractWithCustomerLiabilityRevenueRecognized
22765000
CY2020 us-gaap Contract With Customer Liability Revenue Recognized
ContractWithCustomerLiabilityRevenueRecognized
61872000
CY2022 us-gaap Contract With Customer Performance Obligation Satisfied In Previous Period
ContractWithCustomerPerformanceObligationSatisfiedInPreviousPeriod
13661000
CY2021 us-gaap Contract With Customer Performance Obligation Satisfied In Previous Period
ContractWithCustomerPerformanceObligationSatisfiedInPreviousPeriod
5500000
CY2022 imgn Cash And Cash Equivalents Number Of Financial Institutions
CashAndCashEquivalentsNumberOfFinancialInstitutions
3
CY2021Q4 us-gaap Marketable Securities
MarketableSecurities
0
CY2022Q4 us-gaap Marketable Securities
MarketableSecurities
0
CY2022Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
275100000
CY2021Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
478800000
CY2022 us-gaap Capital Expenditures Incurred But Not Yet Paid
CapitalExpendituresIncurredButNotYetPaid
300000
CY2021 us-gaap Capital Expenditures Incurred But Not Yet Paid
CapitalExpendituresIncurredButNotYetPaid
200000
CY2022Q4 us-gaap Finance Lease Liability
FinanceLeaseLiability
0
CY2022Q4 imgn Accrued Contract Payments Current
AccruedContractPaymentsCurrent
15971000
CY2021Q4 imgn Accrued Contract Payments Current
AccruedContractPaymentsCurrent
5558000
CY2022Q4 imgn Accrued Clinical Trial Costs Current
AccruedClinicalTrialCostsCurrent
15716000
CY2021Q4 imgn Accrued Clinical Trial Costs Current
AccruedClinicalTrialCostsCurrent
15556000
CY2022Q4 us-gaap Accrued Professional Fees Current
AccruedProfessionalFeesCurrent
2020000
CY2021Q4 us-gaap Accrued Professional Fees Current
AccruedProfessionalFeesCurrent
839000
CY2022Q4 us-gaap Accrued Employee Benefits Current
AccruedEmployeeBenefitsCurrent
340000
CY2021Q4 us-gaap Accrued Employee Benefits Current
AccruedEmployeeBenefitsCurrent
40000
CY2022Q4 imgn Accrued Public Reporting Charges Current
AccruedPublicReportingChargesCurrent
265000
CY2021Q4 imgn Accrued Public Reporting Charges Current
AccruedPublicReportingChargesCurrent
309000
CY2022Q4 imgn Accrued Tax Provision Current
AccruedTaxProvisionCurrent
1218000
CY2022Q4 imgn Other Current Accrued Liabilities
OtherCurrentAccruedLiabilities
3253000
CY2021Q4 imgn Other Current Accrued Liabilities
OtherCurrentAccruedLiabilities
775000
CY2022Q4 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
38783000
CY2021Q4 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
23077000
CY2021 us-gaap Asset Impairment Charges
AssetImpairmentCharges
0
CY2022 us-gaap Asset Impairment Charges
AssetImpairmentCharges
0
CY2021 imgn Income Tax Reconciliation Federal Orphan Drug Credit
IncomeTaxReconciliationFederalOrphanDrugCredit
7429000
CY2022 imgn Share Based Compensation Arrangement By Share Based Payment Award Awards Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardsOutstandingNumber
33264000
CY2021 imgn Share Based Compensation Arrangement By Share Based Payment Award Awards Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardsOutstandingNumber
21296000
CY2020 imgn Share Based Compensation Arrangement By Share Based Payment Award Awards Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardsOutstandingNumber
18459000
CY2022 us-gaap Incremental Common Shares Attributable To Share Based Payment Arrangements
IncrementalCommonSharesAttributableToShareBasedPaymentArrangements
1596000
CY2021 us-gaap Incremental Common Shares Attributable To Share Based Payment Arrangements
IncrementalCommonSharesAttributableToShareBasedPaymentArrangements
2546000
CY2020 us-gaap Incremental Common Shares Attributable To Share Based Payment Arrangements
IncrementalCommonSharesAttributableToShareBasedPaymentArrangements
1301000
CY2020 us-gaap Debt Instrument Convertible Number Of Equity Instruments
DebtInstrumentConvertibleNumberOfEquityInstruments
501000
CY2020 us-gaap Incremental Common Shares Attributable To Conversion Of Debt Securities
IncrementalCommonSharesAttributableToConversionOfDebtSecurities
501000
CY2022 imgn Share Based Compensation Arrangement By Share Based Payment Award Number Of Plans
ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfPlans
3
CY2022Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
2600000
CY2022 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested In Period Fair Value1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1
25442000
CY2021 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested In Period Fair Value1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1
15839000
CY2020 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested In Period Fair Value1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1
11465000
CY2022 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercises In Period Total Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue
451000
CY2021 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercises In Period Total Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue
3322000
CY2020 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercises In Period Total Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue
746000
CY2022 us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
1905000
CY2021 us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
3769000
CY2020 us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
1471000
CY2022 us-gaap Number Of Operating Segments
NumberOfOperatingSegments
1
CY2022Q4 imgn License Agreement Development Milestone Payments Receivable Included In Accounts Receivable
LicenseAgreementDevelopmentMilestonePaymentsReceivableIncludedInAccountsReceivable
10000000.0
CY2022Q4 us-gaap Contract With Customer Asset Gross
ContractWithCustomerAssetGross
125000000.0
CY2022Q4 us-gaap Provision For Doubtful Accounts
ProvisionForDoubtfulAccounts
2600000
CY2022 us-gaap Provision For Doubtful Accounts
ProvisionForDoubtfulAccounts
313000
CY2022Q4 us-gaap Allowance For Doubtful Accounts Receivable Current
AllowanceForDoubtfulAccountsReceivableCurrent
313000
CY2022Q4 imgn Raw Materials Non Current
RawMaterialsNonCurrent
15952000
CY2022Q4 imgn Inventory Finished Goods Non Current
InventoryFinishedGoodsNonCurrent
244000
CY2022Q4 us-gaap Inventory Noncurrent
InventoryNoncurrent
16196000
CY2022Q4 us-gaap Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
35741000
CY2021Q4 us-gaap Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
34350000
CY2022Q4 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
31364000
CY2021Q4 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
29687000
CY2022Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
4377000
CY2021Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
4663000
CY2022 us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
1800000
CY2021 us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
2000000.0
CY2020 us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
2100000
CY2020 imgn Cost Basis To Liquidate Property And Equipment
CostBasisToLiquidatePropertyAndEquipment
7500000
CY2022 imgn Accumulated Depreciation Impairment Liquidate Equipment
AccumulatedDepreciationImpairmentLiquidateEquipment
6800000
CY2020 imgn Income Tax Reconciliation Federal Orphan Drug Credit
IncomeTaxReconciliationFederalOrphanDrugCredit
6218000
CY2022 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-221711000
CY2021 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-139303000
CY2020 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-44372000
CY2022 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-221711000
CY2021 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-139303000
CY2020 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-44372000
CY2020 us-gaap Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate
EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
0.21
CY2021 us-gaap Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate
EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
0.21
CY2022 us-gaap Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate
EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
0.21
CY2022 us-gaap Income Tax Reconciliation Income Tax Expense Benefit At Federal Statutory Income Tax Rate
IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate
-46559000
CY2021 us-gaap Income Tax Reconciliation Income Tax Expense Benefit At Federal Statutory Income Tax Rate
IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate
-29254000
CY2020 us-gaap Income Tax Reconciliation Income Tax Expense Benefit At Federal Statutory Income Tax Rate
IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate
-9318000
CY2022 us-gaap Income Tax Reconciliation Nondeductible Expense
IncomeTaxReconciliationNondeductibleExpense
454000
CY2021 us-gaap Income Tax Reconciliation Nondeductible Expense
IncomeTaxReconciliationNondeductibleExpense
606000
CY2020 us-gaap Income Tax Reconciliation Nondeductible Expense
IncomeTaxReconciliationNondeductibleExpense
157000
CY2022 imgn Intra Entity Transfer Intangible Assets
IntraEntityTransferIntangibleAssets
90720000
CY2022 us-gaap Income Tax Reconciliation Nondeductible Expense Share Based Compensation Cost
IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost
769000
CY2021 us-gaap Income Tax Reconciliation Nondeductible Expense Share Based Compensation Cost
IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost
420000
CY2020 us-gaap Income Tax Reconciliation Nondeductible Expense Share Based Compensation Cost
IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost
201000
CY2022 us-gaap Income Tax Reconciliation State And Local Income Taxes
IncomeTaxReconciliationStateAndLocalIncomeTaxes
29304000
CY2021 us-gaap Income Tax Reconciliation State And Local Income Taxes
IncomeTaxReconciliationStateAndLocalIncomeTaxes
-7376000
CY2020 us-gaap Income Tax Reconciliation State And Local Income Taxes
IncomeTaxReconciliationStateAndLocalIncomeTaxes
-2250000
CY2022 us-gaap Income Tax Reconciliation Change In Deferred Tax Assets Valuation Allowance
IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance
-75683000
CY2021 us-gaap Income Tax Reconciliation Change In Deferred Tax Assets Valuation Allowance
IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance
46987000
CY2020 us-gaap Income Tax Reconciliation Change In Deferred Tax Assets Valuation Allowance
IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance
15175000
CY2022 us-gaap Income Tax Reconciliation Tax Credits Research
IncomeTaxReconciliationTaxCreditsResearch
2030000
CY2021 us-gaap Income Tax Reconciliation Tax Credits Research
IncomeTaxReconciliationTaxCreditsResearch
575000
CY2020 us-gaap Income Tax Reconciliation Tax Credits Research
IncomeTaxReconciliationTaxCreditsResearch
228000
CY2022 imgn Income Tax Reconciliation Federal Orphan Drug Credit
IncomeTaxReconciliationFederalOrphanDrugCredit
9286000
CY2021 imgn Income Tax Reconciliation Expired Carryforward
IncomeTaxReconciliationExpiredCarryforward
345000
CY2020 imgn Income Tax Reconciliation Expired Carryforward
IncomeTaxReconciliationExpiredCarryforward
419000
CY2022 imgn Effective Income Tax Rate Reconciliation Tax Credit Lease Incentive Amount
EffectiveIncomeTaxRateReconciliationTaxCreditLeaseIncentiveAmount
-878000
CY2021 imgn Effective Income Tax Rate Reconciliation Tax Credit Lease Incentive Amount
EffectiveIncomeTaxRateReconciliationTaxCreditLeaseIncentiveAmount
-4789000
CY2021 imgn Effective Income Tax Rate Reconciliation Stock Option Expiration Amount
EffectiveIncomeTaxRateReconciliationStockOptionExpirationAmount
1065000
CY2020 imgn Effective Income Tax Rate Reconciliation Stock Option Expiration Amount
EffectiveIncomeTaxRateReconciliationStockOptionExpirationAmount
2062000
CY2022 us-gaap Income Tax Reconciliation Foreign Income Tax Rate Differential
IncomeTaxReconciliationForeignIncomeTaxRateDifferential
14407000
CY2022 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
1218000
CY2021 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
0
CY2020 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
0
CY2022Q4 us-gaap Deferred Tax Assets Operating Loss Carryforwards
DeferredTaxAssetsOperatingLossCarryforwards
115047000
CY2021Q4 us-gaap Deferred Tax Assets Operating Loss Carryforwards
DeferredTaxAssetsOperatingLossCarryforwards
264773000
CY2022Q4 us-gaap Deferred Tax Assets Tax Credit Carryforwards Research
DeferredTaxAssetsTaxCreditCarryforwardsResearch
103155000
CY2021Q4 us-gaap Deferred Tax Assets Tax Credit Carryforwards Research
DeferredTaxAssetsTaxCreditCarryforwardsResearch
92832000
CY2022Q4 imgn Deferred Tax Assets Property And Other Intangible Assets
DeferredTaxAssetsPropertyAndOtherIntangibleAssets
1452000
CY2021Q4 imgn Deferred Tax Assets Property And Other Intangible Assets
DeferredTaxAssetsPropertyAndOtherIntangibleAssets
1150000
CY2022Q4 us-gaap Deferred Tax Assets Deferred Income
DeferredTaxAssetsDeferredIncome
14561000
CY2021Q4 us-gaap Deferred Tax Assets Deferred Income
DeferredTaxAssetsDeferredIncome
25153000
CY2022Q4 us-gaap Deferred Tax Assets Tax Deferred Expense Compensation And Benefits Share Based Compensation Cost
DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost
18783000
CY2021Q4 us-gaap Deferred Tax Assets Tax Deferred Expense Compensation And Benefits Share Based Compensation Cost
DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost
12195000
CY2022Q4 imgn Deferred Tax Assets Operating Lease Liability
DeferredTaxAssetsOperatingLeaseLiability
4421000
CY2021Q4 imgn Deferred Tax Assets Operating Lease Liability
DeferredTaxAssetsOperatingLeaseLiability
5170000
CY2022Q4 us-gaap Deferred Tax Assets Tax Deferred Expense Reserves And Accruals Other
DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsOther
3144000
CY2021Q4 us-gaap Deferred Tax Assets Tax Deferred Expense Reserves And Accruals Other
DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsOther
1737000
CY2022Q4 imgn Deferred Tax Assets Tax Deferred Expense Reserves And Accruals Royalty Sale
DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsRoyaltySale
8393000
CY2021Q4 imgn Deferred Tax Assets Tax Deferred Expense Reserves And Accruals Royalty Sale
DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsRoyaltySale
10247000
CY2022Q4 imgn Deferred Tax Asset Research And Development Capitalization
DeferredTaxAssetResearchAndDevelopmentCapitalization
68150000
CY2022Q4 us-gaap Deferred Tax Assets Gross
DeferredTaxAssetsGross
337106000
CY2021Q4 us-gaap Deferred Tax Assets Gross
DeferredTaxAssetsGross
413257000
CY2022Q4 imgn Deferred Tax Liabilities Operating Lease Right Of Use Asset
DeferredTaxLiabilitiesOperatingLeaseRightOfUseAsset
2967000
CY2021Q4 imgn Deferred Tax Liabilities Operating Lease Right Of Use Asset
DeferredTaxLiabilitiesOperatingLeaseRightOfUseAsset
3386000
CY2022Q4 imgn Deferred Tax Liabilities Royalty Sale
DeferredTaxLiabilitiesRoyaltySale
107000
CY2021Q4 imgn Deferred Tax Liabilities Royalty Sale
DeferredTaxLiabilitiesRoyaltySale
158000
CY2022Q4 us-gaap Deferred Income Tax Liabilities
DeferredIncomeTaxLiabilities
3074000
CY2021Q4 us-gaap Deferred Income Tax Liabilities
DeferredIncomeTaxLiabilities
3544000
CY2022Q4 us-gaap Deferred Tax Assets Valuation Allowance
DeferredTaxAssetsValuationAllowance
334032000
CY2021Q4 us-gaap Deferred Tax Assets Valuation Allowance
DeferredTaxAssetsValuationAllowance
409713000
CY2022 us-gaap Valuation Allowance Deferred Tax Asset Change In Amount
ValuationAllowanceDeferredTaxAssetChangeInAmount
75700000
CY2022 imgn Ownership Control Increase Decrease Under Section382 Percentage
OwnershipControlIncreaseDecreaseUnderSection382Percentage
0
CY2021 us-gaap Tax Adjustments Settlements And Unusual Provisions
TaxAdjustmentsSettlementsAndUnusualProvisions
0
CY2022 us-gaap Tax Adjustments Settlements And Unusual Provisions
TaxAdjustmentsSettlementsAndUnusualProvisions
0
CY2022Q4 us-gaap Common Stock Capital Shares Reserved For Future Issuance
CommonStockCapitalSharesReservedForFutureIssuance
56000000.0
CY2021Q3 us-gaap Class Of Warrant Or Right Exercise Price Of Warrants Or Rights1
ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
0.01
CY2021Q4 us-gaap Class Of Warrant Or Right Exercise Price Of Warrants Or Rights1
ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
0.01
CY2021Q4 us-gaap Shares Issued Price Per Share
SharesIssuedPricePerShare
6.60
CY2022 imgn Number Of Real Estate Leases
NumberOfRealEstateLeases
1
CY2022 us-gaap Lessee Operating Lease Existence Of Option To Extend
LesseeOperatingLeaseExistenceOfOptionToExtend
true
CY2020 us-gaap Operating Lease Expense
OperatingLeaseExpense
4000000.0
CY2021 us-gaap Operating Lease Expense
OperatingLeaseExpense
4000000.0
CY2022 us-gaap Operating Lease Expense
OperatingLeaseExpense
4000000.0
CY2021 us-gaap Operating Lease Payments
OperatingLeasePayments
5300000
CY2022 us-gaap Operating Lease Payments
OperatingLeasePayments
5300000
CY2022Q4 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
10200000
CY2022Q4 us-gaap Operating Lease Liability
OperatingLeaseLiability
15200000
CY2022Q4 us-gaap Operating Lease Weighted Average Remaining Lease Term1
OperatingLeaseWeightedAverageRemainingLeaseTerm1
P3Y3M
CY2022Q4 us-gaap Operating Lease Weighted Average Discount Rate Percent
OperatingLeaseWeightedAverageDiscountRatePercent
0.11
CY2022 imgn Aggregate Adjustment To Right Of Use Asset
AggregateAdjustmentToRightOfUseAsset
1000000
CY2022Q4 us-gaap Lessee Operating Lease Liability Payments Due Next Twelve Months
LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths
5503000
CY2022Q4 us-gaap Lessee Operating Lease Liability Payments Due Year Two
LesseeOperatingLeaseLiabilityPaymentsDueYearTwo
5522000
CY2022Q4 us-gaap Lessee Operating Lease Liability Payments Due Year Three
LesseeOperatingLeaseLiabilityPaymentsDueYearThree
5543000
CY2022Q4 us-gaap Lessee Operating Lease Liability Payments Due Year Four
LesseeOperatingLeaseLiabilityPaymentsDueYearFour
1429000
CY2022Q4 us-gaap Lessee Operating Lease Liability Payments Due Year Five
LesseeOperatingLeaseLiabilityPaymentsDueYearFive
13000
CY2022Q4 us-gaap Lessee Operating Lease Liability Payments Due
LesseeOperatingLeaseLiabilityPaymentsDue
18010000
CY2022Q4 us-gaap Lessee Operating Lease Liability Undiscounted Excess Amount
LesseeOperatingLeaseLiabilityUndiscountedExcessAmount
2766000
CY2022Q4 us-gaap Operating Lease Liability
OperatingLeaseLiability
15244000
CY2022 us-gaap Variable Lease Cost
VariableLeaseCost
3800000
CY2022 us-gaap Sublease Income
SubleaseIncome
1100000
CY2021 us-gaap Sublease Income
SubleaseIncome
4900000
CY2022Q2 imgn Sub Lessee Lease Incentive Payable
SubLesseeLeaseIncentivePayable
4000000.0
CY2022Q2 imgn Payment Of Sub Lessee Lease Incentive
PaymentOfSubLesseeLeaseIncentive
1800000
CY2022Q4 imgn Sub Lessee Lease Incentive Payable
SubLesseeLeaseIncentivePayable
4000000.0
CY2022 imgn Sublease Minimum Future Rental Payment Receivable Forgiven
SubleaseMinimumFutureRentalPaymentReceivableForgiven
4600000
CY2022 us-gaap Impairment Of Leasehold
ImpairmentOfLeasehold
0
CY2022 us-gaap Repayments Of Related Party Debt
RepaymentsOfRelatedPartyDebt
5000000.0
CY2022 imgn Defined Contribution Plan Employee Contribution Limit Percentage Of Salary
DefinedContributionPlanEmployeeContributionLimitPercentageOfSalary
1
CY2022 us-gaap Defined Contribution Plan Employer Matching Contribution Percent
DefinedContributionPlanEmployerMatchingContributionPercent
0.50
CY2022 us-gaap Defined Contribution Plan Maximum Annual Contributions Per Employee Percent
DefinedContributionPlanMaximumAnnualContributionsPerEmployeePercent
0.06
CY2022 us-gaap Defined Contribution Plan Cost Recognized
DefinedContributionPlanCostRecognized
1000000.0
CY2021 us-gaap Defined Contribution Plan Cost Recognized
DefinedContributionPlanCostRecognized
500000
CY2020 us-gaap Defined Contribution Plan Cost Recognized
DefinedContributionPlanCostRecognized
400000

Files In Submission

Name View Source Status
0001558370-23-002558-index-headers.html Edgar Link pending
0001558370-23-002558-index.html Edgar Link pending
0001558370-23-002558.txt Edgar Link pending
0001558370-23-002558-xbrl.zip Edgar Link pending
Financial_Report.xlsx Edgar Link pending
FilingSummary.xml Edgar Link unprocessable
imgn-20221231.xsd Edgar Link pending
imgn-20221231x10k.htm Edgar Link pending
imgn-20221231xex10d12c.htm Edgar Link pending
imgn-20221231xex10d12d.htm Edgar Link pending
imgn-20221231xex10d12f.htm Edgar Link pending
imgn-20221231xex10d15.htm Edgar Link pending
imgn-20221231xex10d19.htm Edgar Link pending
imgn-20221231xex10d20.htm Edgar Link pending
imgn-20221231xex10d23.htm Edgar Link pending
imgn-20221231xex10d23a.htm Edgar Link pending
imgn-20221231xex10d24.htm Edgar Link pending
imgn-20221231xex10d27.htm Edgar Link pending
imgn-20221231xex10d27b.htm Edgar Link pending
imgn-20221231xex21.htm Edgar Link pending
imgn-20221231xex23.htm Edgar Link pending
imgn-20221231xex31d1.htm Edgar Link pending
imgn-20221231xex31d2.htm Edgar Link pending
imgn-20221231xex32.htm Edgar Link pending
imgn-20221231xex4d3.htm Edgar Link pending
MetaLinks.json Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
imgn-20221231_def.xml Edgar Link unprocessable
imgn-20221231_lab.xml Edgar Link unprocessable
imgn-20221231_pre.xml Edgar Link unprocessable
imgn-20221231x10k_htm.xml Edgar Link completed
R34.htm Edgar Link pending
R35.htm Edgar Link pending
R36.htm Edgar Link pending
R37.htm Edgar Link pending
R38.htm Edgar Link pending
R39.htm Edgar Link pending
R4.htm Edgar Link pending
R40.htm Edgar Link pending
R41.htm Edgar Link pending
R42.htm Edgar Link pending
R43.htm Edgar Link pending
R44.htm Edgar Link pending
R45.htm Edgar Link pending
R46.htm Edgar Link pending
R47.htm Edgar Link pending
R48.htm Edgar Link pending
R49.htm Edgar Link pending
R5.htm Edgar Link pending
R50.htm Edgar Link pending
R51.htm Edgar Link pending
R52.htm Edgar Link pending
R53.htm Edgar Link pending
R54.htm Edgar Link pending
R55.htm Edgar Link pending
R56.htm Edgar Link pending
R57.htm Edgar Link pending
R58.htm Edgar Link pending
R59.htm Edgar Link pending
R6.htm Edgar Link pending
R60.htm Edgar Link pending
R61.htm Edgar Link pending
R62.htm Edgar Link pending
R63.htm Edgar Link pending
R64.htm Edgar Link pending
R65.htm Edgar Link pending
R66.htm Edgar Link pending
R67.htm Edgar Link pending
R68.htm Edgar Link pending
R69.htm Edgar Link pending
R7.htm Edgar Link pending
R70.htm Edgar Link pending
R71.htm Edgar Link pending
R72.htm Edgar Link pending
R73.htm Edgar Link pending
R74.htm Edgar Link pending
R75.htm Edgar Link pending
R76.htm Edgar Link pending
R77.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending
imgn-20221231_cal.xml Edgar Link unprocessable